In the context of prostate cancer, tumor recurrence after androgen-deprivation therapy is due to the emergence of castration-resistant prostate cancer (CRPC), which is associated with increased AR activity that can be targeted by second-generation anti-androgen therapies (Watson et al., 2015). Here, AR is linked to prostate carcinoma.